Chemoprevention of hepatocellular carcinoma in chronic hepatitis C

Recent Results in Cancer Research

Volumn 188, Issue , 2011, Pages 85-99

  Morgan, Timothy R ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BETA CRYPTOXANTHIN; CAFFEIC ACID; CAPSAICIN; CAROTENOID; CURCUMIN; EPIGALLOCATECHIN GALLATE; FARNOQUINONE; FLUTAMIDE; GLYCYRRHIZIC ACID; INOSITOL; INTERFERON; MENADIONE; NEOMINOPHAGEN C; OCTREOTIDE; PEGINTERFERON; PERETINOIN; PLACEBO; QUERCETIN; RESVERATROL; RETINOL; RETINOL DERIVATIVE; RIBAVIRIN; S ADENOSYLMETHIONINE; SORAFENIB; TAMOXIFEN; TRIPTORELIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; XIAO CHAI HU TANG;

ABSENCE OF SIDE EFFECTS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHEILITIS; CHEMICAL CARCINOGENESIS; CHEMOEMBOLIZATION; CHRONIC HEPATITIS; COFFEE; CONJUNCTIVITIS; DIET SUPPLEMENTATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DRY SKIN; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS;

EID: 79551525006     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10858-7_7     Document Type: Article

References (66)

1. Altekruse SF, McGlynn KA et al (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27(9):1485-1491
2. Arase Y, Ikeda K et al (1997) The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79(8):1494-1500
3. Backus LI, Boothroyd DB et al (2007) Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46(1):37-47
4. Benten D, Keller G et al (2009) Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 11(9):934-944
5. Bjelakovic G, Nikolova D et al (2004) Antioxidant supplements for prevention of gastrointestinal cancers: A systematic review and meta-analysis. Lancet 364(9441):1219-1228
6. Blonski W, Reddy KR (2008) Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 12(3):661-674, x
7. Borbath I, Leclercq I et al (2007) The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 43(11): 1755-1763
8. Bosch FX, Ribes J et al (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2):191-211, v
9. Bravi F, Bosetti C et al (2007) Coffee drinking and hepatocellular carcinoma risk: A meta-analysis. Hepatology 46(2):430-435
10. Bravi F, Bosetti C et al (2009) Coffee drinking and hepatocellular carcinoma: An update. Hepatology 50(4):1317-1318
11. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208-1236.
12. Bruno S, Stroffolini T et al (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 45(3):579-587.
13. Choo QL, Kuo G et al (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902):359-362 Davis GL, Balart LA et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321(22):1501-1506
14. Davis GL, Alter MJ et al (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138(2):513-521, 521 e511-516
15. Di Bisceglie AM, Osmack P et al (2005) Chemoprevention of hepatocellular carcinoma: Use of tamoxifen in an animal model of hepatocarcinogenesis. J Lab Clin Med 145(3):134-138
16. Di Bisceglie AM, Shiffman ML et al (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359(23):2429-2441
17. Dimitroulopoulos D, Xinopoulos D et al (2007) Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebocontrolled trial. World J Gastroenterol 13(23): 3164-3170
18. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557-2576.
19. Feinstone SM, Kapikian AZ et al (1975) Transfusionassociated hepatitis not due to viral hepatitis type A or B. N Engl J Med 292(15):767-770
20. Freedman ND, Everhart JE et al (2009) Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 50(5): 1360-1369
21. Garcea R, Daino L et al (1989) Inhibition of promotion and persistent nodule growth by S-adenosyl- L-methionine in rat liver carcinogenesis: Role of remodeling and apoptosis. Cancer Res 49(7): 1850-1856
22. George SL, Bacon BR et al (2009) Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year followup of 150 patients. Hepatology 49(3):729-738.
23. Habu D, Shiomi S et al (2004) Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 292(3):358-361
24. Hirayama C, Okumura M et al (1989) A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 24(6):715-719
25. Ismail MF, Ali DA et al (2009) Chemoprevention of rat liver toxicity and carcinogenesis by Spirulina. Int J Biol Sci 5(4):377-387
26. Kim Y, Ji SK et al (2000) Modulation of liver microsomal monooxygenase system by dietary n-6/n-3 ratios in rat hepatocarcinogenesis. Nutr Cancer 37(1):65-72
27. Kojima S, Okuno M et al (2004) Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Int J Oncol 24(4):797-805
28. Kota J, Chivukula RR et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005-1017.
29. Kouroumalis E, Skordilis P et al (1998) Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study. Gut 42(3):442-447
30. Kuo G, Choo QL et al (1989) An assay for circulating antibodies to a major etiologic virus of human non- A, non-B hepatitis. Science 244(4902):362-364.
31. Kuroiwa-Trzmielina J, de Conti A et al (2009) Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: Efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 124(11):2520-2527
32. La Vecchia C (2005) Coffee, liver enzymes, cirrhosis and liver cancer. J Hepatol 42(4):444-446.
33. Larsson SC, Wolk A (2007) Coffee consumption and risk of liver cancer: A meta-analysis. Gastroenterology 132(5):1740-1745
34. Liu Q, Song Y et al (2006) A useful agent for chemoprevention of hepatocellular carcinoma? Cancer Biol Ther 5(12):1674-1676
35. Llovet JM, Ricci S et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
36. Lok AS, Seeff LB et al (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136(1):138-148
37. Lu SC, Mato JM (2008) S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol 23(Suppl 1):S73-77
38. Lu SC, Ramani K et al (2009) S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology 50(2):462-471
39. Manesis EK, Giannoulis G et al (1995) Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial. Hepatology 21(6): 1535-1542
40. Mann CD, Neal CP et al (2009) Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 18(1):13-25
41. Modi AA, Feld JJ et al (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 51(1):201-209
42. Moriwaki H, Shimizu M et al (2007) Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects. Hepatol Res 37(Suppl 2): S299-302
43. Muto Y, Moriwaki H et al (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334(24):1561-1567 (Pubitemid 26177483)
44. Muto Y, Moriwaki H et al (1999) Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 340(13):1046-1047
45. Nishino H (2007) Prevention of hepatocellular carcinoma in chronic viral hepatitis patients with cirrhosis by carotenoid mixture. Recent Results Cancer Res 174:67-71
46. Nishino H (2009) Phytochemicals in hepatocellular cancer prevention. Nutr Cancer 61(6):789-791
47. Nishino H, Murakoshi M et al (2009) Cancer prevention by carotenoids. Arch Biochem Biophys 483(2):165-168
48. Oka H, Yamamoto S et al (1995) Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 76(5):743-749
49. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533-543
50. Rahman KM, Sugie S et al (1999) Modulating effects of diets high in omega-3 and omega-6 fatty acids in initiation and postinitiation stages of diethylnitrosamine-induced hepatocarcinogenesis in rats. Jpn J Cancer Res 90(1):31-39
51. Rayman MP (2005) Selenium in cancer prevention: A review of the evidence and mechanism of action. Proc Nutr Soc 64(4):527-542
52. Ruhl CE, Everhart JE (2005a) Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 128(1):24-32
53. Ruhl CE, Everhart JE (2005b) Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129(6):1928-1936
54. Seeff LB (2009) The history of the "natural history" of hepatitis C (1968-2009). Liver Int 29(Suppl 1):89-99
55. Shichiri M, Fukai N et al (2009) Rifampicin as an oral angiogenesis inhibitor targeting hepatic cancers. Cancer Res 69(11):4760-4768
56. Shiffman ML, Morishima C et al (2009) Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the Halt-C trial. Gastroenterology 50(Suppl 1):S22
57. Shimizu M, Takai K et al (2009) Strategy and mechanism for the prevention of hepatocellular carcinoma: Phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 100(3):369-374
58. Takami A, Nakao S et al (1999) Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 69(1):24-26
59. Tamori A, Habu D et al (2007) Potential role of vitamin K(2) as a chemopreventive agent against hepatocellular carcinoma. Hepatol Res 37(Suppl 2):S303-307
60. Tanaka T, Nishikawa A et al (1990) Inhibitory effects of chlorogenic acid, reserpine, polyprenoic acid (E-5166), or coffee on hepatocarcinogenesis in rats and hamsters. Basic Life Sci 52:429-440
61. Tarao K, Fujiyama S et al (2005) Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virusassociated liver cirrhosis. Cancer Epidemiol Biomark Prev 14(1):164-169
62. Tatsuta M, Iishi H et al (1997) Chemoprevention by amiloride against experimental hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats. Cancer Lett 119(1): 109-113
63. Veldt BJ, Heathcote EJ et al (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147(10):677-684
64. Wei W, Chua MS et al (2009) Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 8:76
65. Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32(1):28-44
66. Zhu B, Liu GT et al (2006) Chemoprevention of bicyclol against hepatic preneoplastic lesions. Cancer Biol Ther 5(12):1665-1673